Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
6.51
-0.05 (-0.76%)
At close: Apr 22, 2026, 4:00 PM EDT
6.42
-0.09 (-1.43%)
After-hours: Apr 22, 2026, 5:00 PM EDT
Aligos Therapeutics Employees
Aligos Therapeutics had 82 employees as of December 31, 2025. The number of employees increased by 12 or 17.14% compared to the previous year.
Employees
82
Change (1Y)
12
Growth (1Y)
17.14%
Revenue / Employee
$26,659
Profits / Employee
-$295,037
Market Cap
40.28M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 82 | 12 | 17.14% |
| Dec 31, 2024 | 70 | 4 | 6.06% |
| Sep 30, 2024 | 68 | 0 | - |
| Jun 30, 2024 | 68 | 0 | - |
| Mar 31, 2024 | 67 | -2 | -2.90% |
| Dec 31, 2023 | 66 | -17 | -20.48% |
| Sep 30, 2023 | 68 | -21 | -23.60% |
| Jun 30, 2023 | 68 | -21 | -23.60% |
| Mar 31, 2023 | 69 | -26 | -27.37% |
| Dec 31, 2022 | 83 | -10 | -10.75% |
| Sep 30, 2022 | 89 | 3 | 3.49% |
| Jun 30, 2022 | 89 | 3 | 3.49% |
| Mar 31, 2022 | 95 | 26 | 37.68% |
| Dec 31, 2021 | 93 | 19 | 25.68% |
| Sep 30, 2021 | 86 | 13 | 17.81% |
| Jun 30, 2021 | 86 | 19 | 28.36% |
| Mar 31, 2021 | 69 | 8 | 13.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evaxion | 46 |
| NextCure | 40 |
| Werewolf Therapeutics | 39 |
| Palatin Technologies | 29 |
| Veru Inc. | 20 |
| RenovoRx | 17 |
| Sensei Biotherapeutics | 15 |
| Atara Biotherapeutics | 14 |
ALGS News
- 6 days ago - Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates - Benzinga
- 6 days ago - Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - GlobeNewsWire
- 8 days ago - Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation - GlobeNewsWire
- 6 weeks ago - Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates - GlobeNewsWire